Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Diacon

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Microbiology|August 29, 2014
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibilityElizabeth M Streicher, Kashmeel Maharaj, Talita York, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Tuberculosis (Edinburgh, Scotland)|July 20, 2011
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosisKerryn Matthews, Katalin A Wilkinson, Barbara Kalsdorf, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
Frontiers in Immunology|October 9, 2024
Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humansAndrew Fiore-Gartland, Himangi Srivastava, Aaron Seese, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
The New England Journal of Medicine|October 4, 2018
Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisOlivier Van Der Meeren, Mark Hatherill, Videlis Nduba, et al.
The New England Journal of Medicine|October 30, 2019
Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisDereck R Tait, Mark Hatherill, Olivier Van Der Meeren, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Clinical Microbiology|August 29, 2014
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibilityElizabeth M Streicher, Kashmeel Maharaj, Talita York, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populationsRuth Bowness, Martin J Boeree, Rob Aarnoutse, et al.
Tuberculosis (Edinburgh, Scotland)|July 20, 2011
Predominance of interleukin-22 over interleukin-17 at the site of disease in human tuberculosisKerryn Matthews, Katalin A Wilkinson, Barbara Kalsdorf, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
Frontiers in Immunology|October 9, 2024
Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humansAndrew Fiore-Gartland, Himangi Srivastava, Aaron Seese, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
The New England Journal of Medicine|October 4, 2018
Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisOlivier Van Der Meeren, Mark Hatherill, Videlis Nduba, et al.
The New England Journal of Medicine|October 30, 2019
Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent TuberculosisDereck R Tait, Mark Hatherill, Olivier Van Der Meeren, et al.
The Lancet. Respiratory Medicine|December 11, 2020
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trialTracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 2